Isofol Medical (ISOFOL) Q2 2025 earnings summary

Executive summary

• Transitioned from planning to execution phase, marked by a successful, oversubscribed rights issue raising SEK 91 million gross and strengthening the financial position for continued clinical development.

• Positive progress in the phase Ib/II clinical study for arfolitixorin, with the first dose cohort completed and the second cohort underway.

• Constructive pre-IND meeting with the FDA validated the clinical development plan for arfolitixorin in the U.S.

• Japanese partner Solasia Pharma K.K. to finance and conduct phase II/III studies in Japan, expanding the clinical program's reach.

Financial highlights

• No revenue reported due to current business stage; R&D and operating expenses increased with the start of a new clinical study in April.

• Q2 net result was SEK -14.7 million, compared to SEK -11 million in Q2 last year, mainly due to higher clinical and regulatory expenses.

• January–June result was SEK -28.3 million, versus SEK -19.5 million for the same period last year.

• Cash and cash equivalents at June 30, 2025, were SEK 65.7 million, down from SEK 119.2 million a year earlier, prior to the rights issue.

• Cash flow for the quarter was SEK -17 million, compared to SEK -9 million a year earlier.

Capital allocation and financing

• Rights issue completed in early July, oversubscribed to 120%, raising SEK 91 million gross and SEK 84 million net after transaction expenses.

• New and existing shareholders participated, including strategic partner Solasia Pharma K.K.

• No loans outstanding; all funding from equity, and R&D costs expensed as incurred.